GCP
PCVX icon

GSA Capital Partners’s Vaxcyte PCVX Stock Holding History

GSA Capital Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,798
Closed -$286K – 1986
2025
Q2 		$286K Buy
+8,798
New +$288K 0.02% 1289
2025
Q1 		– Sell
-3,584
Closed -$293K – 1980
2024
Q4 		$293K Buy
+3,584
New +$356K 0.02% 1218
2023
Q1 		– Sell
-10,894
Closed -$522K – 1828
2022
Q4 		$522K Buy
+10,894
New +$428K 0.06% 571

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

GSA Capital Partners's PCVX Position: Q3 2025 in Review

GSA Capital Partners sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 8,798 shares — an estimated $286K sold.

GSA Capital Partners first reported a position in PCVX in Q4 2022 and held it in 3 quarters. The position peaked at $522K in Q4 2022. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

  • GSA Capital Partners reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 8,798 Vaxcyte shares in Q3 2025, an estimated $286K.
  • GSA Capital Partners first reported a position in Vaxcyte in Q4 2022 and held it in 3 quarters.
  • GSA Capital Partners's Vaxcyte position peaked at $522K in Q4 2022.
  • 285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.